FORWARD FEATURES CALENDAR

Solutions

Middle market private equity firm HGGC is to sell Serena Software to UK-based Micro Focus International plc (Micro Focus) an international software product group, at an enterprise value of USD540 million in cash. Headquartered in San Mateo, California, Serena is the world’s largest independent provider of IT application development and deployment solution, helping nearly one million users in more than 2,500 global organizations streamline their IT processes to deliver applications faster, improve IT service performance and reduce IT costs. Since HGGC and company founder Doug Troxel acquired the business in 2014, Serena has made significant progress, reducing net debt by
Thoma Bravo is in exclusive negotiations to sell InfoVista, a market leader in service performance assurance solutions for IP-based network and application services, to Apax Partners. Financial terms of the agreement have not been disclosed. Thoma Bravo acquired Paris-based InfoVista in April 2012 through a complex take-private acquisition on the Euronext exchange, setting the stage for the company to accelerate its growth as a private company. During its partnership with Thoma Bravo, InfoVista more than doubled its size through organic growth and complementary acquisitions. “We couldn’t be more proud of our partnership with [InfoVista CEO] Philippe Ozanian and his management
SK Capital Partners (SK Capita), a private investment firm focused on the specialty materials, has completed the previously announced sale of IBA Molecular (IBAM) to funds advised by private equity firm CapVest Partners.  IBA Molecular was jointly owned by SK Capital and Ion Beam Applications S.A. prior to the sale. Terms of the transaction were not disclosed. Since SK Capital acquired 60 per cent of IBA Molecular in April 2012, the Company has successfully executed on a number of operational improvement initiatives and strategic transactions. Jamshid Keynejad, Founding Partner of SK Capital, says: “The Company’s leading position in its core
The Riverside Company has signed an agreement to sell Diatron Group (Diatron) to STRATEC Biomedical AG of Germany.  Budapest-based Diatron develops, manufactures, and markets compact hematology analyzers for the human medical and veterinary markets. The transaction is expected to close near the end of this month. Riverside invested in Diatron in late 2005, and worked extensively to grow the company organically, through new product development, and via international expansion. Riverside also completed the add-on of MetroLab in 2008, delivering new products, capabilities and customers. “We’re proud of the work we’ve done to help Diatron thrive during our ownership,” says Riverside
Trivergance, in partnership with Falcon Investment Advisors and Landon Capital Partners, has acquired Clarus Commerce from global venture capital and growth equity investment firm, Norwest Venture Partners.  The management team at Clarus has built a dynamic company that capitalises on the rapidly growing market opportunity at the intersection of eCommerce and subscription-based loyalty and rewards solutions. Specifically, Clarus has developed and manages a proprietary, flexible and scalable membership and benefit management technology platform. This platform delivers to consumers and its “white-label” partners a suite of valuable benefits that drive enhanced loyalty and customer engagement. Clarus offers its own portfolio of
LakePharma has acquired Blue Sky BioServices, a CRO specialising in protein and antibody production and assay services.  The combined company will be known as LakePharma, and is now the largest dedicated biologics CRO in the United States, providing a broad range of protein and antibody-related development services to the pharmaceutical and biotechnology markets. Blue Sky BioServices is a portfolio company of Ampersand Capital Partners and as part of the transaction, Ampersand made an investment into LakePharma to support growth initiatives. Bringing together LakePharma’s world class expertise in antibody development, protein expression and characterization, molecular biology and process development with Blue
YFM Equity Partners (YFM) and Octopus Investments (Octopus) have sold their stake in Callstream Group (Callstream) for an undisclosed sum to J2 Global, Inc.  Callstream is a leading national provider of cloud-based call management technology to the UK insurance, travel and retail markets. The acquisition by J2 Global provides a full exit for all funds. Callstream was backed by the Octopus Apollo Venture Capital Trust (‘VCT’) plc, advised by Octopus Investments (Octopus) and British Smaller Companies VCT plc and British Smaller Companies VCT2 plc, both advised by YFM Private Equity Limited (YFM). Mick Crosthwaite, CEO of Callstream, says: “Callstream has
Boston-based private equity firm Bunker Hill Capital has sold its portfolio company, The Smith & Wollensky Restaurant Group (SWRG) to Danu Partners, a private investment firm based in Ireland and a sub-licensee of SWRG which opened a restaurant in London in June, 2015.  David Jacquin, Founder and Managing Director of North Point Advisors, advised Bunker Hill Capital and SWRG on the sale. Mark DeBlois, a Managing Partner of Bunker Hill Capital, says: “It has been our privilege to work with SWRG CEO Mike Feighery and his team in opening two new locations at Atlantic Wharf, Boston and in London with
YFM Equity Partners (YFM) and Octopus Investments (Octopus) have sold their stake in Callstream Group Limited (Callstream) for an undisclosed sum to J2 Global, Inc.  Callstream is a leading national provider of cloud-based call management technology to the UK insurance, travel and retail markets.  Today’s acquisition by J2 Global provides a full exit for all funds.   Callstream was backed by the Octopus Apollo Venture Capital Trust (‘VCT’) plc, advised by Octopus Investments (Octopus) and British Smaller Companies VCT plc and British Smaller Companies VCT2 plc, both advised by YFM Private Equity Limited (YFM).   Mick Crosthwaite, CEO of Callstream,
Meghan McAlpine
By Meghan McAlpine – Given the uptick in new funds being raised, competition for investors’ capital has increased significantly.  Investors are being more thorough in the diligence process and almost always requesting more information than what’s presented in a standard DDQ. In order to compete for this capital, fund managers are providing a substantial amount of information to investors.   The industry as a whole is seeing an increase in transparency, which has been insisted upon by investors over the past several years. Performance, while a very important factor, is only part of the criteria that investors are considering when determining whether or not to

Events

12 November, 2026 – 8:00 am

Directory Listings